GIP and obesity due to melanocortin 4 receptor deficiency: Pharmacological obesity treatment with second-generation GLP1 agonists or double GLP1-GIP agonists has revolutionized obesity management in recent years, and related studies may provide interesting insight about therapeutic weight loss and body composition – notably independent of structured prevention strategies to minimize muscle loss (such as enhanced protein dietary intake or exercise training programmes), that were not included in the treatment protocols.